Artificial Intelligence to Decode Cancer Mechanism: Beyond Patient Stratification for Precision Oncology
Open Access
- 12 August 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 1177
- https://doi.org/10.3389/fphar.2020.01177
Abstract
The multitude of multi-omics data generated cost-effectively using advanced high-throughput technologies has imposed challenging domain for research in Artificial Intelligence (AI). Data curation poses a significant challenge as different parameters, instruments, and sample preparations approaches are employed for generating these big data sets. AI could reduce the fuzziness and randomness in data handling and build a platform for the data ecosystem, and thus serve as the primary choice for data mining and big data analysis to make informed decisions. However, AI implication remains intricate for researchers/clinicians lacking specific training in computational tools and informatics. Cancer is a major cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018. Certain cancers, such as pancreatic and gastric cancers, are detected only after they have reached their advanced stages with frequent relapses. Cancer is one of the most complex diseases affecting a range of organs with diverse disease progression mechanisms and the effectors ranging from gene-epigenetics to a wide array of metabolites. Hence a comprehensive study, including genomics, epi-genomics, transcriptomics, proteomics, and metabolomics, along with the medical/mass-spectrometry imaging, patient clinical history, treatments provided, genetics, and disease endemicity, is essential. Cancer Moonshot℠ Research Initiatives by NIH National Cancer Institute aims to collect as much information as possible from different regions of the world and make a cancer data repository. AI could play an immense role in (a) analysis of complex and heterogeneous data sets (multi-omics and/or inter-omics), (b) data integration to provide a holistic disease molecular mechanism, (c) identification of diagnostic and prognostic markers, and (d) monitor patient’s response to drugs/treatments and recovery. AI enables precision disease management well beyond the prevalent disease stratification patterns, such as differential expression and supervised classification. This review highlights critical advances and challenges in omics data analysis, dealing with data variability from lab-to-lab, and data integration. We also describe methods used in data mining and AI methods to obtain robust results for precision medicine from “big” data. In the future, AI could be expanded to achieve ground-breaking progress in disease management.This publication has 206 references indexed in Scilit:
- Promoter cross-talk via a shared enhancer explains paternally biased expression of Nctc1 at the Igf2/H19/Nctc1 imprinted locusNucleic Acids Research, 2012
- The UCSC Cancer Genomics Browser: update 2013Nucleic Acids Research, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Serum metabolomics as a novel diagnostic approach for gastrointestinal cancerBiomedical Chromatography, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Integrating multiple ‘omics’ analysis for microbial biology: application and methodologiesMicrobiology, 2010
- DNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeNature, 2008
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast CancerCancer Research, 2008
- The complete genome of an individual by massively parallel DNA sequencingNature, 2008
- MethyCancer: the database of human DNA methylation and cancerNucleic Acids Research, 2007